Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 201

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Erlotinib for Frontline Treatment of Advanced Non–Small Cell Lung Cancer: a Phase II Study

Giaccone, Giuseppe, Gallegos Ruiz, Marielle, Le Chevalier, Thierry, Thatcher, Nick, Smit, Egbert, Rodriguez, Jose Antonio, Janne, Pasi, Oulid-Aissa, Dalila, Soria, Jean-Charles·2006·Clinical Cancer Research

Abstract

Purpose: Erlotinib has proven activity in pretreated patients with advanced non–small cell lung cancer (NSCLC). We evaluated erlotinib in the frontline treatment of advanced NSCLC and assessed biological predictors of outcome. Experimental Design: In this phase II study, chemotherapy-naive patients with stage IIIB/IV NSCLC received oral erlotinib (150 mg/d) until disease progression or unacceptable toxicity occurred. Tumor response was assessed every 6 weeks, and samples were analyzed for potential molecular markers of treatment response and survival. The primary end point was the proportion of patients without disease progression after 6 weeks of treatment. Results: Fifty-three patients were eligible. The overall rate of nonprogression at 6 weeks was 52.8% (28 of 53 patients). Tumor response rate was 22.7%, with 1 complete response, 11 partial responses, and 16 cases of stable disease. Responses were seen across most patient clinical characteristics. The median duration of tumor response was 333 days; median overall survival was 391 days; and median time to disease progression was 84 days. Erlotinib was well tolerated, the main treatment-related adverse events being mild-to-moderate rash and diarrhea. Histologic material for biological studies was available in 29 cases. Four of five responders and one patient with stable disease had a classic epidermal growth factor receptor tyrosine kinase mutation. Two progressing patients exhibited epidermal growth factor receptor point mutations (one with T790M mutation), and K-ras mutations were detected in 10 nonresponders. Conclusions: Erlotinib shows significant antitumor activity in the first-line treatment of advanced NSCLC and may be a viable alternative to chemotherapy. Patient selection cannot easily be based on clinical or biological variables.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-06-0260

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 201

Metadata

Authors
Giaccone, G., Gallegos Ruiz, M., Le Chevalier, T., Thatcher, N., Smit, E., Rodriguez, J. A., Janne, P., Oulid-Aissa, D., & Soria, J.-C.
Venue
Clinical Cancer Research
Published
2006-10-15
Volume
12
Issue
20
Pages
6049-6055
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2032573089
Cited by
201
References
6
FWCI
23.08
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Erlotinib for Frontline Treatment of Advanced Non–Small Cell Lung Cancer: a Phase II Study. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-06-0260
The paper
Giaccone, G., Gallegos Ruiz, M., Le Chevalier, T., Thatcher, N., Smit, E., Rodriguez, J. A., Janne, P., Oulid-Aissa, D., & Soria, J.-C. (2006). Erlotinib for Frontline Treatment of Advanced Non–Small Cell Lung Cancer: a Phase II Study. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-06-0260

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.